Lanthanum Orifarm

Lanthanum carbonate, the active ingredient in Lanthanum Orifarm, is a phosphate binder presented as an oral tablet for gastrointestinal administration. It reduces dietary phosphate absorption and is indicated for the management of hyperphosphatemia in chronic kidney disease patients, particularly those receiving dialysis.

The product is manufactured in the European Union and meets EU quality standards, ensuring consistent potency and safety for patients. GNH USA supplies Lanthanum Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lanthanum Orifarm is a phosphate binder used to control elevated serum phosphate in renal‑related conditions. - Chronic kidney disease with hyperphosphatemia: helps lower serum phosphate levels. - End‑stage renal disease (ESRD) requiring phosphate control: reduces dietary phosphate absorption. - Dialysis patients with hyperphosphatemia: assists in maintaining target phosphate concentrations.

Lanthanum Orifarm may cause adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea: occasional upset stomach. - Constipation: reduced bowel movements. - Abdominal pain: mild discomfort. - Diarrhea: loose stools. - Flatulence: increased gas. - Dyspepsia: indigestion.

Serious or Rare Side Effects: - Severe constipation or bowel obstruction: requires medical attention. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzymes. - Severe abdominal pain: persistent or worsening pain. - Hypophosphatemia: excessively low phosphate levels. - Hypercalcemia: elevated calcium levels, especially when combined with calcium supplements.

Before initiating therapy, consider the following precautions. - Monitor serum phosphate: adjust dose based on laboratory results. - Assess calcium balance: avoid concurrent high calcium intake. - Gastrointestinal disorders: use cautiously in patients with bowel obstruction or severe constipation. - Hypersensitivity: discontinue if allergic reaction occurs. - Renal function: dose may need adjustment in severe renal impairment. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Lanthanum carbonate can affect the absorption of several co‑administered drugs.

Major Interactions (Avoid): - Tetracycline antibiotics: binding reduces antibiotic efficacy. - Fluoroquinolone antibiotics: decreased absorption when taken together. - Levothyroxine: may lower thyroid hormone levels. - Iron supplements: significant reduction in iron absorption. - Vitamin B12: decreased uptake with concurrent use.

Moderate Interactions (Monitor Closely): - Calcium carbonate: may diminish phosphate‑binding capacity. - Vitamin D analogues: monitor calcium‑phosphate product. - Magnesium‑containing antacids: possible reduced effectiveness of lanthanum. - Sevelamer: assess combined phosphate‑binding effect. - Proton pump inhibitors: may alter gastric pH and affect binding efficiency.